List of Excipients in Branded Drug CALCITONIN SALMON

Generic Drugs Containing CALCITONIN SALMON

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	calcitonin salmon	24201-400	ACETIC ACID
Hikma Pharmaceuticals USA Inc	calcitonin salmon	24201-400	PHENOL
Hikma Pharmaceuticals USA Inc	calcitonin salmon	24201-400	SODIUM ACETATE
Hikma Pharmaceuticals USA Inc	calcitonin salmon	24201-400	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in CALCITONIN SALMON?

# Of NDCs	Excipient
9	ACETIC ACID
2	BENZALKONIUM CHLORIDE
5	HYDROCHLORIC ACID
3	NITROGEN

Last updated: August 9, 2026

Calcitonin salmon is a low-growth, safety-constrained peptide market in which excipient innovation has greater commercial value in nasal delivery, preservative reduction, stability improvement, and differentiated packaging than in conventional injectable products. The strongest opportunities are reformulations that improve tolerability, dose consistency, room-temperature stability, or adherence while preserving the drug's established regulatory pathway. Broad new-indication strategies face substantial commercial and clinical barriers because of alternative osteoporosis therapies and FDA concerns regarding long-term malignancy risk.

Calcitonin Salmon Excipient Strategy and Commercial Opportunities

What is the commercial position of calcitonin salmon?

Calcitonin salmon is a synthetic 32-amino-acid peptide used primarily in injectable and intranasal products. Approved uses include treatment of hypercalcemia, Paget's disease of bone, and postmenopausal osteoporosis in patients more than five years after menopause when alternative treatments are unsuitable or not tolerated [1].

The product is commercially mature. Its main competitive disadvantages are:

• Lower clinical use than bisphosphonates, denosumab, teriparatide, abaloparatide, and romosozumab.
• Limited duration of recommended use in osteoporosis.
• Intranasal absorption variability.
• Local nasal irritation and congestion.
• Regulatory concern regarding a possible malignancy signal in long-term clinical studies [2].
• Limited reimbursement and guideline preference in many osteoporosis settings.

The commercial opportunity is therefore concentrated in lifecycle management rather than primary molecule discovery.

Product and route comparison

Attribute	Injectable calcitonin salmon	Intranasal calcitonin salmon
Typical product type	Solution for injection	Metered nasal spray
Main commercial uses	Hypercalcemia, Paget's disease, osteoporosis	Osteoporosis, historically
Formulation challenge	Peptide stability, sterility, adsorption, injection tolerability	Mucosal absorption, dose uniformity, nasal irritation
Excipient burden	Relatively low	Higher because of preservation and nasal delivery requirements
Key differentiation route	Ready-to-use presentation, storage stability, reduced injection burden	Absorption enhancer, preservative-free delivery, device accuracy
Regulatory risk	Sterility and injectable quality	Local tolerance, systemic exposure variability, device performance
Commercial attractiveness	Institutional and acute-care niches	Chronic-use niche with greater reformulation potential

What excipients are used in calcitonin salmon products?

The core excipient system depends on route and product design. Approved calcitonin salmon injections generally use an acidic aqueous vehicle with sodium chloride and acetate buffering components. Intranasal products use a simple aqueous formulation with sodium chloride, pH adjustment, and a preservative such as benzalkonium chloride in multidose presentations [3,4].

Injectable formulation strategy

A conventional injectable formulation may include:

• Water for injection.
• Sodium chloride for isotonicity.
• Acetic acid and sodium acetate for pH control.
• Hydrochloric acid or sodium hydroxide for final pH adjustment.
• Container-closure components with low peptide adsorption.

The principal formulation risks are peptide aggregation, oxidation, deamidation, adsorption to glass or polymer surfaces, and potency loss during storage. Calcitonin salmon is a relatively small peptide, but its biological activity depends on maintaining a defined conformation and avoiding fibrillation or surface-mediated loss.

A commercial injectable product can gain value through:

1. A ready-to-use prefilled syringe.
2. Reduced withdrawal and preparation requirements.
3. Lower extractables and leachables risk.
4. Improved cold-chain robustness.
5. Lower container adsorption.
6. A smaller injection volume.
7. Compatibility with hospital and emergency-use workflows.

The opportunity is strongest for hypercalcemia and inpatient use, where preparation time, sterility assurance, and dosing reliability may have more value than consumer convenience.

Intranasal formulation strategy

Intranasal calcitonin salmon is more dependent on excipient selection. The nasal mucosa presents a substantial barrier to peptide absorption. A formulation must deliver adequate exposure without causing persistent epithelial irritation.

The excipient platform may include:

• Isotonicity agents such as sodium chloride.
• Acidic pH adjustment systems.
• Preservatives for multidose containers.
• Mucoadhesive polymers.
• Enzyme inhibitors.
• Permeation enhancers.
• Surfactants or solubilizing agents.
• Buffer systems compatible with nasal tolerability.

The commercial challenge is that excipients that increase absorption can also increase irritation, alter mucociliary clearance, or damage epithelial integrity. A successful formulation must show a useful balance between systemic exposure and local safety.

What excipients offer the strongest commercial differentiation?

Preservative-free nasal delivery

Benzalkonium chloride has been used in nasal products, but repeated exposure can raise local tolerability concerns. A preservative-free unit-dose or tightly controlled multidose device could support differentiation through:

• Lower preservative exposure.
• Reduced nasal irritation risk.
• Better suitability for chronic or intermittent use.
• Cleaner positioning for patients with chronic rhinitis or sensitive nasal mucosa.

The commercial tradeoff is higher packaging cost and greater microbial-control requirements. The sponsor would need to demonstrate container integrity, in-use stability, microbial robustness, and accurate delivery over the labeled use period.

Absorption-enhancing excipients

Calcitonin salmon has low and variable nasal bioavailability. Absorption enhancers can improve exposure, but the development burden is high. Candidate classes include fatty-acid derivatives, bile-salt-related systems, surfactants, cyclodextrins, and selected mucoadhesive polymers.

The most attractive strategy is not maximum absorption. It is reproducible exposure at the lowest effective enhancer concentration. A formulation that produces lower peak-to-trough variability may have greater clinical and regulatory value than one that produces the highest mean exposure.

Key development endpoints include:

• Absolute and relative bioavailability.
• Dose proportionality.
• Interpatient variability.
• Nasal epithelial tolerability.
• Effect of congestion, rhinitis, and seasonal allergy.
• Long-term local pathology.
• Recovery after repeated administration.

Mucoadhesive systems

Mucoadhesive polymers can extend residence time and reduce post-dose drainage. Potential materials include selected cellulose derivatives, polyvinylpyrrolidone, carbomers, and biodegradable polymers.

These materials can create new risks:

• Altered spray plume and droplet size.
• Inconsistent dosing after storage.
• Excessive residence time.
• Impaired mucociliary clearance.
• Increased local irritation.
• Difficult device compatibility.

The preferred commercial design is a low-viscosity formulation that provides modest residence-time improvement without turning the product into a gel-forming nasal system.

Stabilizers and aggregation control

The formulation should be screened for peptide loss at air-liquid interfaces, container surfaces, and pump components. Stabilization options may include:

• Low levels of nonionic surfactants.
• Polyols such as sorbitol or mannitol.
• Amino acids.
• Chelating agents where metal-catalyzed degradation is relevant.
• Optimized ionic strength.
• Oxygen-controlled filling and packaging.

Any stabilizer must be evaluated for injection safety or nasal tolerability, depending on route. Excipient selection should be linked to a defined degradation mechanism rather than added empirically.

What formulation patents could protect calcitonin salmon products?

The most defensible patent positions would generally cover the formulation architecture, delivery device, manufacturing process, or use of a specific excipient combination rather than calcitonin salmon itself.

Potential composition-of-matter and formulation claims

A sponsor could seek claims directed to:

• Calcitonin salmon at a defined concentration range.
• A specified pH and osmolality window.
• A preservative-free aqueous nasal formulation.
• A particular absorption enhancer at a defined concentration.
• A peptide-to-excipient ratio.
• A specified impurity or aggregate limit.
• A formulation stable for a defined period at controlled room temperature.
• A low-dose formulation with a defined pharmacokinetic profile.

Patent strength will depend on whether the combination produces an unexpected technical effect, such as improved bioavailability without additional nasal irritation. Generic claims covering only routine excipients in conventional ranges are more vulnerable to obviousness challenges.

Device and packaging patents

Device claims may provide stronger practical protection than broad excipient claims. Relevant subject matter includes:

• Metered-dose nasal pumps.
• Unit-dose blister or ampoule systems.
• Dose counters.
• Airless containers.
• Low-adsorption pump components.
• Formulation-device combinations that preserve spray performance.
• Packaging that limits oxidation or microbial contamination.

A formulation patent can be designed around a device-specific performance requirement, such as delivered dose uniformity after storage, priming, or repeated actuation.

Manufacturing and process patents

Manufacturing claims may address:

• Controlled addition of calcitonin salmon to the excipient vehicle.
• Low-shear mixing.
• Temperature-controlled filling.
• Oxygen reduction.
• Sterile filtration.
• Lyophilization and reconstitution.
• Removal of aggregates or particulates.
• Specific terminal sterilization alternatives.

Process protection is commercially useful when the process produces a measurable quality advantage that competitors cannot easily reproduce without infringing.

When does calcitonin salmon lose exclusivity?

The original composition and early product patents for calcitonin salmon products are generally mature or expired. Commercial exclusivity now depends more on product-specific formulation, device, regulatory exclusivity, trademarks, manufacturing know-how, and supply reliability.

Exclusivity category	Relevance to calcitonin salmon
Active-ingredient patent	Generally no longer a meaningful barrier
Original injectable product patents	Mature or expired for legacy products
Intranasal formulation patents	Potentially relevant only for specific protected compositions
Device patents	Relevant for proprietary nasal pumps and unit-dose systems
Method-of-use patents	Narrow opportunity because approved uses are established
Orphan-drug exclusivity	Potentially relevant only for a qualifying new indication
New drug product exclusivity	Possible for a genuinely new formulation or clinical use
Trade secrets	Important for peptide handling, filling, and stability control

The practical loss-of-exclusivity question is product-specific. A generic or authorized alternative may be able to enter once applicable patents and regulatory exclusivities expire, but formulation and device patents can delay direct substitution if they cover commercially important product characteristics.

What is the FDA regulatory status of calcitonin salmon?

FDA-approved calcitonin salmon products have historically included injection and nasal spray dosage forms. FDA labeling restricts the osteoporosis indication to postmenopausal patients more than five years after menopause when other treatments are unsuitable or not tolerated [3,4].

FDA also required labeling changes after analyses identified a possible increased malignancy risk associated with calcitonin-salmon products. The risk-benefit profile is therefore more favorable in acute hypercalcemia or selected Paget's disease cases than in routine long-term osteoporosis treatment [2].

Regulatory implications for excipient changes

A reformulation may require:

• Chemistry, Manufacturing, and Controls comparability.
• Updated stability studies.
• Extractables and leachables testing.
• Device compatibility data.
• Local nasal tolerability studies.
• Delivered-dose uniformity testing.
• Microbial limits or preservative-effectiveness testing.
• Pharmacokinetic bridging.
• Clinical efficacy or safety data if exposure changes materially.

An excipient change that alters absorption can be more consequential than an excipient change in a conventional oral small-molecule product. For nasal calcitonin salmon, the excipient system is part of the delivery mechanism.

Are there Paragraph IV and generic-entry risks?

Generic-entry risk is higher for simple injectable solutions than for differentiated nasal products. An injectable generic can potentially rely on a relatively straightforward formulation and establish pharmaceutical equivalence, subject to FDA requirements.

Nasal products create more complex substitution issues because sameness may depend on:

• Formulation composition.
• Device design.
• Delivered dose.
• Droplet or particle size.
• Spray pattern.
• Plume geometry.
• Priming and repriming behavior.
• Local tolerance.
• Pharmacokinetic comparability.

A Paragraph IV challenge could target listed patents covering the formulation, device, or method of use. The innovator's strongest litigation position would usually involve a narrow formulation-device combination supported by robust stability and delivery data.

Generic launch scenarios

Scenario	Likely commercial effect
Injectable generic enters first	Price erosion and hospital formulary pressure
Nasal generic enters with equivalent device performance	Significant erosion in chronic-use prescriptions
Authorized generic launches	Faster price control by the brand owner
Reformulated nasal product launches before generic entry	Possible preservation of premium pricing
Preservative-free product receives differentiated approval	Potential niche protection, subject to substitution rules
Device patent survives but formulation patent fails	Product may retain a protected delivery channel but face design-around risk

How strong is the patent estate for calcitonin salmon?

The legacy patent estate is likely weak as a broad molecule-based barrier because calcitonin salmon has been marketed for decades. The stronger protection opportunities are narrow and technical:

1. A measurable bioavailability improvement.
2. Reduced local nasal toxicity.
3. A stable formulation with meaningful temperature tolerance.
4. A proprietary delivery device.
5. A manufacturing process that reduces aggregates or potency loss.
6. A new indication supported by controlled clinical evidence.

Patent value should be assessed against design-around ease. A claim covering a specific enhancer may be bypassed with another enhancer. A claim tied to a device, formulation, and performance result can be harder to design around but may also be narrower and more difficult to enforce.

What licensing and commercial opportunities exist?

The best licensing opportunities are likely to involve platform assets rather than the calcitonin salmon molecule itself.

Attractive licensing targets

• Preservative-free nasal delivery technology.
• Peptide absorption-enhancer platforms.
• Low-adsorption injectable containers.
• Prefilled syringe systems.
• Unit-dose nasal devices.
• Room-temperature stabilization technology.
• Manufacturing processes that reduce peptide aggregation.
• Regional rights to legacy products with established regulatory files.

A licensee should value the asset against the limited size of the calcitonin salmon market and the cost of new clinical studies. A technically strong formulation may still have low net present value if it requires extensive clinical development for an indication with inexpensive generic alternatives.

Geographic opportunities

Commercial potential is uneven by region:

• North America: high regulatory scrutiny and generic substitution pressure.
• Europe: historically restrictive views on intranasal calcitonin for osteoporosis.
• Japan and parts of Asia: potential demand in osteoporosis and pain-related bone disorders, subject to local approvals.
• Emerging markets: possible opportunity for low-cost injectable supply, but price competition is intense.
• Hospital markets: more defensible for hypercalcemia treatment than chronic osteoporosis.

What commercial strategy is most defensible?

A sponsor should prioritize an acute-care injectable or a clearly differentiated nasal product rather than a broad osteoporosis relaunch.

The most defensible development sequence is:

1. Establish a low-risk excipient platform using recognized pharmaceutical-grade materials.
2. Select a preservative-free or low-preservative nasal presentation where feasible.
3. Demonstrate dose consistency and reduced local irritation.
4. Pair the formulation with a proprietary device.
5. Build stability data that supports broader distribution.
6. Seek composition, device, and process patents with overlapping claim scope.
7. Position the product for patients who cannot use first-line osteoporosis therapies or for acute hypercalcemia management.
8. Avoid relying on a method-of-use patent alone.

Key Takeaways

• Calcitonin salmon is a mature peptide product with limited growth in routine osteoporosis.
• Excipient innovation is most valuable in intranasal absorption, local tolerability, preservation, and stability.
• Injectable products offer operational differentiation through prefilled, ready-to-use, and low-adsorption presentations.
• Preservative-free nasal delivery and device integration provide the clearest lifecycle-management opportunities.
• Broad molecule patents are unlikely to provide meaningful protection; formulation, device, manufacturing, and performance-based claims are more relevant.
• Generic risk is higher for simple injections and more complex for nasal products.
• FDA safety concerns limit the commercial value of chronic osteoporosis positioning.
• Licensing value depends on development cost, regional reimbursement, generic competition, and the ability to secure overlapping patent claims.

FAQs About Calcitonin Salmon Excipient and Commercial Strategy

Can mannitol be used in calcitonin salmon formulations?

Mannitol can be evaluated as a tonicity modifier or stabilizing excipient, but suitability depends on route, concentration, peptide stability, osmolality, and compatibility with the final container. Nasal tolerability and injection safety must be established separately.

Is benzalkonium chloride necessary in calcitonin salmon nasal spray?

It is not inherently necessary. It is used in some multidose nasal products for antimicrobial preservation, but a preservative-free unit-dose system or alternative preservation strategy may support better local tolerability.

Can an absorption enhancer create new patent protection?

Yes. A specific calcitonin salmon and enhancer combination may support composition or use claims if it provides unexpected bioavailability, lower variability, or improved tolerability. Routine selection of a known enhancer is more vulnerable to obviousness challenges.

Is oral calcitonin salmon commercially attractive?

Oral delivery has high technical potential because it could eliminate injections and nasal administration, but peptide degradation and very low gastrointestinal absorption create substantial formulation and clinical-development risk. An oral product would need a strong delivery platform and a clinically meaningful benefit over established therapies.

Which calcitonin salmon indication offers the best commercial opportunity?

Hypercalcemia and selected Paget's disease cases are more defensible than broad osteoporosis use because they involve acute or specialized treatment settings where injectable delivery and rapid action may have greater value.

References

1. U.S. Food and Drug Administration. (2023). Calcitonin salmon injection prescribing information. FDA labeling database.

2. U.S. Food and Drug Administration. (2013). FDA drug safety communication: New contraindication and warning on malignancy risk for calcitonin-salmon products. FDA.

3. Novartis Pharmaceuticals Corporation. (2017). Miacalcin injection prescribing information. U.S. Food and Drug Administration.

4. Novartis Pharmaceuticals Corporation. (2017). Miacalcin nasal spray prescribing information. U.S. Food and Drug Administration.

5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. Center for Drug Evaluation and Research.

6. European Medicines Agency. (2012). European Medicines Agency recommends limiting long-term use of calcitonin medicines. EMA.